In-licencing of multiple late stage orthobiologics IP assets
The bone grafting market is ripe for disruption as surgeons are forced to compromise between fusion rates, side effects, convenience, and affordability. Locate Bio's ambition is to build a world leading, diversified orthobiologics company with a suite of best-in-class technologies that address the performance limitations of existing products and enable orthopaedic surgeons to improve the lives of people suffering from debilitating conditions.
Locate Bio was looking for additional, complementary acquisition or in-licencing opportunities that would further broaden its portfolio to provide surgeons with a choice of best-in-class technologies and products that address the current challenges of existing products and meet the specific patient- driven clinical need.
The technologies developed by the RCSI Tissue Engineering Research Group had extensive pre-clinical and human data demonstrating their effectiveness in the treatment of both hard and soft tissue defects. These patented technologies were supported by peer reviewed preclinical and clinical data demonstrating their efficacy for the regeneration of bone and cartilage tissues and the treatment of osteomyelitis.
“In-licensing these high-quality, complementary, late-stage assets from RCSI has significantly accelerated Locate Bio’s growth trajectory. The end-to-end process of licensing, technology transfer and continued development of the products has been very well supported by the Innovation Team at RCSI. We have been thoroughly impressed with RCSI’s scientific rigor and innovation, and we look forward to continuing to collaborate as we advance our products towards market approval.”
– John von Benecke, CEO, Locate Bio